1000 SPRING ST, SILVER SPRING, MD
Reports Record Third Quarter 2025 Financial Results
TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
Announces $1 Billion Accelerated Share Repurchase Program
Reports Record Second Quarter 2025 Financial Results
News, Material Contracts
Earnings Release
Annual Report to Security Holders
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Specialized Disclosure Report
Amended Tender Offer Statement by Third Party
Correspondence